Michael M. Abecassis

Michael M. Abecassis

Auto-generated profile, based on publicly available information

Michael M. Abecassis

Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, IL

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
RSRiad Salem
Riad Salem
AGAndrew C. Gordon
Andrew C. Gordon
SMSamdeep Mouli
Samdeep Mouli
RHRyan Hickey
Ryan Hickey
JKJoseph Kallini
Joseph Kallini
RLRobert J. Lewandowski
Robert J. Lewandowski
Background & Aims Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC. Methods From October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility. Of these, 179 patients with BCLC stages A or B met our enrollment criteria and were candidates for cTACE or Y90 therapy. Patients were assigned randomly to groups that received Y90 therapy (n = 24; 50% Child–Pugh A) or cTACE (n = 21; 71% Child–Pugh A). The primary outcome was time to progression (TTP), evaluated by intention-to-treat analysis. Secondary outcomes included safety, rate of response (based on tumor size and necrosis criteria), and Kaplan–Meier survival time. We performed inverse probability of censoring weighting and competing risk analyses. Results Patients in the Y90 radioembolization group had significant longer median TTP (>26 mo) than patients in the cTACE group (6.8 mo; P = .0012) (hazard ratio, 0.122; 95% confidence interval [CI], 0.027–0.557; P = .007). This was confirmed by competing risk and inverse probability of censoring weighting analyses accounting for transplantation or death. A significantly greater proportion of patients in the cTACE group developed diarrhea (21%) than in the Y90 group (0%; P = .031) or hypoalbuminemia (58% in the cTACE group vs 4% in the Y90 group; P < .001). Similar proportions of patients in each group had a response to therapy, marked by necrosis (74% in the cTACE group vs 87% in the Y90 group) (P = .433). The median survival time, censored to liver transplantation, was 17.7 months for the cTACE group (95% CI, 8.3–not calculable) vs 18.6 months for the Y90 group (95% CI, 7.4–32.5) (P = .99). Conclusions In a randomized phase 2 study of patients with HCC of BCLC stages A or B, we found Y90 radioembolization to provide significantly longer TTP than cTACE. Y90 radioembolization provides better tumor control and could reduce drop-out from transplant waitlists. ClinicalTrials.gov no. NCT00956930.

1 December 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
RSRiad Salem
Riad Salem
AGAhmed Gabr
Ahmed Gabr
ARAhsun Riaz
Ahsun Riaz
RMRonald Mora
Ronald Mora
RARehan Ali
Rehan Ali
RLRobert J. Lewandowski
Robert J. Lewandowski

6 March 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LVL. B. VanWagner
L. B. VanWagner
MSM. Serper
M. Serper
RKR. Kang
R. Kang
JLJ. Levitsky
J. Levitsky
SHS. Hohmann
S. Hohmann
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Assessment of major adverse cardiovascular events (MACE) after liver transplantation (LT) has been limited by the lack of a multicenter study with detailed clinical information. An integrated database linking information from the University HealthSystem Consortium and the Organ Procurement and Transplant Network was analyzed using multivariate Poisson regression to assess factors associated with 30‐ and 90‐day MACE after LT (February 2002 to December 2012). MACE was defined as myocardial infarction (MI), heart failure (HF), atrial fibrillation (AF), cardiac arrest, pulmonary embolism, and/or stroke. Of 32 810 recipients, MACE hospitalizations occurred in 8% and 11% of patients at 30 and 90 days, respectively. Recipients with MACE were older and more likely to have a history of nonalcoholic steatohepatitis (NASH), alcoholic cirrhosis, MI, HF, stroke, AF and pulmonary and chronic renal disease than those without MACE. In multivariable analysis, age >65 years (incidence rate ratio [IRR] 2.8, 95% confidence interval [95% CI] 1.8–4.4), alcoholic cirrhosis (IRR 1.6, 95% CI 1.2–2.2), NASH (IRR 1.6, 95% CI 1.1–2.4), pre‐LT creatinine (IRR 1.1, 95% CI 1.04–1.2), baseline AF (IRR 6.9, 95% CI 5.0–9.6) and stroke (IRR 6.3, 95% CI 1.6–25.4) were independently associated with MACE. MACE was associated with lower 1‐year survival after LT (79% vs. 88%, p < 0.0001). In a national database, MACE occurred in 11% of LT recipients and had a negative impact on survival. Pre‐LT AF and stroke substantially increase the risk of MACE, highlighting potentially high‐risk LT candidates.

9 July 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JFJohn J. Friedewald
John J. Friedewald
SKSunil Kurian
Sunil Kurian
RHRaymond L. Heilman
Raymond L. Heilman
TWThomas C Whisenant
Thomas C Whisenant
EPEmilio D. Poggio
Emilio D. Poggio
MAMichael M. Abecassis
Michael M. Abecassis
Non‐invasive biomarkers are needed to monitor stable patients following kidney transplantation (KT), as sub‐clinical acute rejection (subAR), currently detectable only with surveillance biopsies can lead to chronic rejection and graft loss. We conducted a multi‐center study to develop a blood‐based molecular biomarker for subAR using peripheral blood paired with surveillance biopsies and strict clinical phenotyping algorithms for discovery and validation. At a predefined threshold, 72‐75% of KT recipients achieved a negative biomarker test correlating with the absence of subAR (NPV: 78‐88%), while a positive test was obtained in 25‐28% correlating with the presence of subAR (PPV: 47‐61%). The clinical phenotype and biomarker independently and statistically correlated with a composite clinical endpoint (renal function, biopsy‐proven acute rejection, >grade 2 interstitial fibrosis and tubular atrophy), as well as with de novo donor‐specific antibodies. We also found that <50% showed histological improvement of subAR on follow up biopsies despite treatment, and that the biomarker could predict this outcome. Our data suggest that a blood‐based biomarker that reduces the need for the indiscriminate use of invasive surveillance biopsies, and that correlates with transplant outcomes could be used to monitor KT recipients with stable renal function, including after treatment for subAR, potentially improving KT outcomes.

1 December 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
BTBartley Thornburg
Bartley Thornburg
KDKush Desai
Kush Desai
RHRyan Hickey
Ryan Hickey
EHElias Hohlastos
Elias Hohlastos
LKLaura Kulik
Laura Kulik
RSRiad Salem
Riad Salem

13 July 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
LVLisa B. VanWagner
Lisa B. VanWagner
HNHongyan Ning
Hongyan Ning
MWMaureen Whitsett
Maureen Whitsett
JLJosh Levitsky
Josh Levitsky
SUSarah Uttal
Sarah Uttal
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones